Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia drug
Biotech
MapLight raises $373M to plot phase 2 journey for Cobenfy rival
The biotech has started midphase studies in schizophrenia and Alzheimer’s disease psychosis in recent weeks.
Nick Paul Taylor
Jul 28, 2025 10:23am
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
LB Pharma's twist on old Sanofi drug passes schizophrenia test
Jan 8, 2025 7:00am
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Aug 28, 2024 7:53am
Karuna's schizophrenia drug clears blood pressure test
Nov 17, 2023 8:52am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
